News
KOD
39.61
+0.30%
0.12
Healthcare stocks with A+ momentum investors are watching
Seeking Alpha · 1d ago
Kodiak Sciences upgraded to Buy from Neutral at Chardan
TipRanks · 2d ago
This Pitney Bowes Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday
Benzinga · 2d ago
Kodiak Sciences Raised to Buy From Neutral by Chardan Capital
Dow Jones · 2d ago
Kodiak Sciences Price Target Raised to $61.00/Share From $14.00 by Chardan Capital
Dow Jones · 2d ago
Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (ELVN), BioNTech SE (BNTX) and Kodiak Sciences (KOD)
TipRanks · 2d ago
Chardan Capital Upgrades Kodiak Sciences to Buy, Raises Price Target to $61
Benzinga · 2d ago
Analysts Offer Insights on Healthcare Companies: Kodiak Sciences (KOD), IN8bio (INAB) and Ultragenyx Pharmaceutical (RARE)
TipRanks · 2d ago
Weekly Report: what happened at KOD last week (0504-0508)?
Weekly Report · 2d ago
LifeSci Capital Remains a Buy on Kodiak Sciences (KOD)
TipRanks · 5d ago
Kodiak Sciences reports Q1 EPS (94c), consensus ($1.01)
TipRanks · 6d ago
Kodiak Sciences GAAP EPS of -$0.94 beats by $0.07
Seeking Alpha · 6d ago
Kodiak Sciences Q1 EPS $(0.94) Misses $(0.92) Estimate
Benzinga · 6d ago
Kodiak Sciences Q1 net loss narrows as R&D rises
Reuters · 6d ago
Kodiak Sciences Q1 FY26 net loss widens to $58.2 million; R&D expenses rise to $48.5 million
PUBT · 6d ago
KODIAK SCIENCES ANNOUNCES RECENT BUSINESS HIGHLIGHTS AND FIRST QUARTER 2026 FINANCIAL RESULTS
Reuters · 6d ago
*Kodiak Sciences 1Q Loss $58.2M >KOD
Dow Jones · 6d ago
Press Release: Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results
Dow Jones · 6d ago
Press Release: Kodiak Sciences Announces Recent -3-
Dow Jones · 6d ago
Press Release: Kodiak Sciences Announces Recent -2-
Dow Jones · 6d ago
More
Webull provides a variety of real-time KOD stock news. You can receive the latest news about Kodiak Sciences Inc. through multiple platforms. This information may help you make smarter investment decisions.
About KOD
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab tedromer, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy and wet age-related macular degeneration. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate designed to inhibit interleukin-6 (IL-6)-mediated inflammation and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.